Filing Buzzer: Fate Therapeutics Inc: Biotechnology Value Fund L P Opened Big New Position

Filing Buzzer: Fate Therapeutics Inc: Biotechnology Value Fund L P Opened Big New Position

The New Biotechnology Value Fund L P Holding in Fate Therapeutics Inc

Biotechnology Value Fund L P filed with the SEC SC 13G form for Fate Therapeutics Inc. The form can be accessed here: 000092189516006259. As reported in Biotechnology Value Fund L P’s form, the filler as of late owns 9.1% or 3,759,398 shares of the Health Care–company.

Fate Therapeutics Inc stake is a new one for the and it was filed because of activity on November 21, 2016. We feel this shows Biotechnology Value Fund L P’s positive view for the stock.

Fate Therapeutics Inc Institutional Sentiment

Latest Security and Exchange filings show 43 investors own Fate Therapeutics Inc. The institutional ownership in Q3 2015 is low, at 66.38% of the outstanding shares. This is increased by 4650140 the total institutional shares. 22668887 were the shares owned by these institutional investors. In total 7 funds opened new Fate Therapeutics Inc stakes, 18 increased stakes. There were 3 that closed positions and 12 reduced them.

2 managers had the stock in their top Ten. Notable investors are: Board Of Trustees Of The Leland Stanford Junior University, Polaris Venture Management Co. V L.L.C…

Kevin Kotler Broadfin Capital Llc is an institutional investor bullish on Fate Therapeutics Inc, owning 1113986 shares as of Q3 2015 for 0.33% of its portfolio. Mark Kingdon Kingdon Capital Management Llc owns 2402224 shares or 0.62% of its portfolio. MA Polaris Venture Management Company have 8.98% of their stock portfolio for 2473186 shares. Further, Redmile Group Llc reported stake worth 0.23% of its US stock portfolio. The CA Board Of Trustees Of The Leland Stanford Junior University owns 291067 shares. Fate Therapeutics Inc is 0.39% of the manager’s US portfolio.

Business Profile

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment increased to 0.82 in Q2 2016. Its up 0.26, from 0.56 in 2016Q1. The ratio improved, as 7 funds sold all Fate Therapeutics Inc shares owned while 11 reduced positions. 1 funds bought stakes while 9 increased positions. They now own 13.89 million shares or 11.32% less from 15.66 million shares in 2016Q1.

Deutsche Commercial Bank Ag accumulated 17,792 shares or 0% of the stock. Retail Bank Of New York Mellon Corp last reported 0% of its portfolio in the stock. Tocqueville Asset Management L P holds 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 22,000 shares. Retail Bank Of America Corporation De accumulated 28,320 shares or 0% of the stock. Jacobs Levy Equity Management holds 0.01% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 178,647 shares. Fmr accumulated 0% or 4.31M shares. Vanguard has 657,573 shares for 0% of their US portfolio. Board Of Trustees Of The Leland Stanford Junior University last reported 291,067 shares in the company. Kingdon Capital has invested 0.21% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE). Blackrock Institutional Trust Na has 5,728 shares for 0% of their US portfolio. Moreover, Goldman Sachs Gp Inc has 0% invested in Fate Therapeutics Inc (NASDAQ:FATE) for 35,966 shares. Blackrock Advsr Ltd Co reported 4,030 shares or 0% of all its holdings. Lombard Odier Asset Mgmt (Usa) Corp, a New York-based fund reported 256,426 shares. Polaris Venture Co V Limited owns 2.47M shares or 4.51% of their US portfolio. Da Davidson Company accumulated 0% or 720 shares.

Insider Transactions: Since November 23, 2016, the stock had 3 insider purchases, and 0 selling transactions for $1.25 million net activity. Another trade for 375,939 shares valued at $999,998 was made by RASTETTER WILLIAM H on Wednesday, November 23. Coughlin Timothy P bought $149,997 worth of stock or 56,390 shares. $99,997 worth of Fate Therapeutics Inc (NASDAQ:FATE) shares were bought by Storgard Chris.

Analysts await Fate Therapeutics Inc (NASDAQ:FATE) to report earnings on March, 2. They expect $-0.29 EPS, down 11.54% or $0.03 from last year’s $-0.26 per share. After $-0.27 actual EPS reported by Fate Therapeutics Inc for the previous quarter, Wall Street now forecasts 7.41% negative EPS growth.

The stock increased 2.72% or $0.08 on December 1, hitting $3.02. About 214,109 shares traded hands or 5.68% up from the average. Fate Therapeutics Inc (NASDAQ:FATE) has risen 50.00% since April 28, 2016 and is uptrending. It has outperformed by 44.07% the S&P500.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $98.12 million. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. It currently has negative earnings. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Fate Therapeutics Inc (NASDAQ:FATE) Ratings Coverage

Out of 6 analysts covering Fate Therapeutics (NASDAQ:FATE), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $8 is the highest target while $4 is the lowest. The $6.75 average target is 123.51% above today’s ($3.02) stock price. Fate Therapeutics has been the topic of 6 analyst reports since October 6, 2015 according to StockzIntelligence Inc. The stock of Fate Therapeutics Inc (NASDAQ:FATE) earned “Outperform” rating by BMO Capital Markets on Tuesday, April 12. On Tuesday, November 8 the stock rating was maintained by Wedbush with “Outperform”. The rating was initiated by Wells Fargo with “Outperform” on Friday, December 4. Roth Capital initiated the shares of FATE in a report on Thursday, September 22 with “Buy” rating. TH Capital initiated Fate Therapeutics Inc (NASDAQ:FATE) on Thursday, September 22 with “Buy” rating. The stock of Fate Therapeutics Inc (NASDAQ:FATE) has “Outperform” rating given on Tuesday, October 6 by Raymond James.

More news for Fate Therapeutics Inc (NASDAQ:FATE) were recently published by: Medgadget.com, which released: “Fate Therapeutics, Inc Clinical Trial Reviews and Clinical Trail Assessment …” on September 14, 2016. 247Wallst.com‘s article titled: “Could This Be a Turning Point for Fate Therapeutics?” and published on June 20, 2016 is yet another important article.

According to Zacks Investment Research, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.”

FATE Company Profile

Fate Therapeutics, Inc. (Fate Therapeutics), incorporated on April 27, 2007, is a clinical-stage biopharmaceutical company. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. The Firm programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. The Company’s adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment